Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04798586 · BASELINE

Baseline characteristics

MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple Myeloma · Source last updated 2024-09-27

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms
  1. counts
    1. group Id
      BG000
      value
      4
    units
    Participants
groups
  1. description
    Participants received an initial priming dose of 600 microgram per kilogram elranatamab subcutaneously on Cycle 0 Day 1 (7 days prior to Cycle 1 Day 1). During treatment cycle, participants were administered 1000 microgram per kilogram elranatamab weekly during each cycle (each cycle was of 3 weeks).
    id
    BG000
    title
    Elranatamab
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          spread
          10.03
          value
          64.0
    dispersion Type
    STANDARD_DEVIATION
    param Type
    MEAN
    title
    Age, Continuous
    unit Of Measure
    Years
  2. classes
    1. categories
      1. measurements
        1. comment
          Data cannot be reported due to low enrollment in one category and would lead to risk of re-identification of participants.
          group Id
          BG000
          value
          NA
        title
        Female
      2. measurements
        1. comment
          Data cannot be reported due to low enrollment in one category and would lead to risk of re-identification of participants.
          group Id
          BG000
          value
          NA
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
  3. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          4
        title
        Asian
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Race/Ethnicity, Customized
    unit Of Measure
    Participants
population Description
Safety Analysis Set (SAS) included all enrolled participants who received at least 1 dose of study intervention.
Complete source fields
denoms
  1. counts
    1. group Id
      BG000
      value
      4
    units
    Participants
groups
  1. description
    Participants received an initial priming dose of 600 microgram per kilogram elranatamab subcutaneously on Cycle 0 Day 1 (7 days prior to Cycle 1 Day 1). During treatment cycle, participants were administered 1000 microgram per kilogram elranatamab weekly during each cycle (each cycle was of 3 weeks).
    id
    BG000
    title
    Elranatamab
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          spread
          10.03
          value
          64.0
    dispersion Type
    STANDARD_DEVIATION
    param Type
    MEAN
    title
    Age, Continuous
    unit Of Measure
    Years
  2. classes
    1. categories
      1. measurements
        1. comment
          Data cannot be reported due to low enrollment in one category and would lead to risk of re-identification of participants.
          group Id
          BG000
          value
          NA
        title
        Female
      2. measurements
        1. comment
          Data cannot be reported due to low enrollment in one category and would lead to risk of re-identification of participants.
          group Id
          BG000
          value
          NA
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
  3. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          4
        title
        Asian
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Race/Ethnicity, Customized
    unit Of Measure
    Participants
population Description
Safety Analysis Set (SAS) included all enrolled participants who received at least 1 dose of study intervention.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice